Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, Jun Takeuchi, So Nagai, Hiroki Yokoyama, Ichiro Sakuma, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi

Open source

DOI: 10.1136/bmjopen-2021-056885
Published: 2022-05
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2021-056885,
  title = {Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)},
  author = {Hiroshi Nomoto and Sho Furusawa and Akinobu Nakamura and Jun Takeuchi and So Nagai and Hiroki Yokoyama and Ichiro Sakuma and Shinji Taneda and Yoshio Kurihara and Shin Aoki and Aika Miya and Hiraku Kameda and Kyu Yong Cho and Tatsuya Atsumi and Hideaki Miyoshi},
  year = {2022},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2021-056885},
  url = {https://doi.org/10.1136/bmjopen-2021-056885}
}

RIS

TY  - JOUR
TI  - Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
AU  - Hiroshi Nomoto
AU  - Sho Furusawa
AU  - Akinobu Nakamura
AU  - Jun Takeuchi
AU  - So Nagai
AU  - Hiroki Yokoyama
AU  - Ichiro Sakuma
AU  - Shinji Taneda
AU  - Yoshio Kurihara
AU  - Shin Aoki
AU  - Aika Miya
AU  - Hiraku Kameda
AU  - Kyu Yong Cho
AU  - Tatsuya Atsumi
AU  - Hideaki Miyoshi
PY  - 2022
JO  - BMJ Open
DO  - 10.1136/bmjopen-2021-056885
UR  - https://doi.org/10.1136/bmjopen-2021-056885
ER  -

APA

Nomoto, H., Furusawa, S., Nakamura, A., Takeuchi, J., Nagai, S., Yokoyama, H., Sakuma, I., Taneda, S., Kurihara, Y., Aoki, S., Miya, A., Kameda, H., Cho, K. Y., Atsumi, T., & Miyoshi, H. (2022). Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). BMJ Open. https://doi.org/10.1136/bmjopen-2021-056885

Source records

crossref · retrieved 2026-09-27T04:04:01.266Z